Trials / Completed
CompletedNCT03322137
Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 208 (actual)
- Sponsor
- Sienna Biopharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo when administered topically for the treatment of pruritus associated with psoriasis vulgaris (PV) and PV itself.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SNA-120 | Pegcantratinib ointment |
| DRUG | Vehicle | Placebo ointment to mimic Pegcantratinib ointment |
Timeline
- Start date
- 2017-10-10
- Primary completion
- 2018-09-10
- Completion
- 2018-10-22
- First posted
- 2017-10-26
- Last updated
- 2019-02-08
Locations
38 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03322137. Inclusion in this directory is not an endorsement.